Revance Therapeutics, Inc.

Form 4

December 15, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

5 Relationship of Reporting Person(s) to

3235-0287

Expires:

January 31, 2005

0.5

response...

Estimated average burden hours per

OMB APPROVAL

if no longer subject to Section 16. Form 4 or Form 5 obligations

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

2 Jaguar Nama and Tiakar or Trading

may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

Common

Common

Stock

Stock

12/11/2014

(Print or Type Responses)

1. Name and Address of Reporting Person *

	SILVERNAIL LAUREN P			Symbol Revance Therapeutics, Inc. [RVNC]					Issuer (Check all applicable)			
	(Last)	(First) NCE THERAPE	(Middle)	3. Date of (Month/D 12/11/20	-	ansaction			DirectorX_ Officer (give	10%	Owner r (specify	
INC., 7555 GATEWAY BOULEVARD			,	12/11/2014					below) CFO, Secretary & EVP Corp Dev.			
					f Amendment, Date Original d(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
NEWARK, CA 94560 (City) (State) (Zip)			Tabl	a I - Non-D	arivetivo	Sacur	ities Acar	Person	f or Ranaficial			
	1.Title of Security (Instr. 3)	Title of 2. Transaction Date 2A. Deemed curity (Month/Day/Year) Execution Date		ned n Date, if	3. 4. Securities Acquired te, if Transaction(A) or Disposed of (D Code (Instr. 3, 4 and 5) Year) (Instr. 8) (A) or			equired d of (D)	Securities Form: Direct Indirect Beneficially (D) or Beneficia Owned Indirect (I) Ownershi Following (Instr. 4) (Instr. 4) Reported Transaction(s) (Instr. 3 and 4)			
	Common Stock	12/11/2014			P	200	A	\$ 17.73	14,200	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

P

780

Persons who respond to the collection of **SEC 1474** information contained in this form are not required to respond unless the form

14,980

 $1,000 \ \underline{^{(1)}}$

D

D

Edgar Filing: Revance Therapeutics, Inc. - Form 4

displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative	2.	3. Transaction Date (Month/Day/Year)		4.	5. onNumber	6. Date Exerc		7. Titl		8. Price of Derivative	9. Nu Deriv
Security (Instr. 3)	Conversion or Exercise Price of Derivative Security	(Month/Day/Tear)	any (Month/Day/Year)	Code (Instr. 8)	of			Under Secur	rlying	Security (Instr. 5)	Secur Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

SILVERNAIL LAUREN P C/O REVANCE THERAPEUTICS, INC. 7555 GATEWAY BOULEVARD NEWARK, CA 94560

CFO, Secretary & EVP Corp Dev.

Signatures

/s/ Gordon Ho, Attorney-in-fact

12/12/2014

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 1,000 shares acquired by the Reporting Person under the Issuer 2014 Employee Stock Purchase Plan on June 30, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2